Sunday 18 October 2026
Export PRLD’s income statement to Excel — free account
Prelude Therapeutics Incorporated
PRLD Healthcare Biotechnology
Prelude Therapeutics Incorporated’s revenue for fiscal 2025 (year ended December 2025) was $12.1 million, up 73.4% from fiscal 2024. In the quarter to June 2026, revenue grew 42.6%, EPS grew 65.9% and free cash flow grew 40.3%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
3.26
0.06
−1.81%
Follow PRLD
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
(103.99%) | (99.45%) | (95.25%) | (57.73%) | |
| (76.56%) | (62.81%) | (59.64%) | (39.76%) | ||
ROIC |
(2,115.06%) | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(244.73%) | (172.11%) | (163.46%) | (49.89%) | |
Average Days of Receivables |
— | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(1.32) | (0.73) | (0.53) | (0.34) | |
Free Cash Flow |
(100.28) | (56.37) | (43.76) | (33.25) | |
Capital Expenditures |
(0.12) | (0.07) | — | — | |
| Other line items | |||||
Cash ROIC |
(88.36%) | (32.80%) | (30.87%) | (11.65%) | |
Accounts Receivable Turnover |
— | 0.00 | 0.00 | 0.00 | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 492.69% | 381.68% | 309.63% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 117.06% | 105.08% | 90.92% | |
Share Based Compensation of Revenue |
0.00% | 62.24% | 48.65% | 36.99% | |
Operating CF/Net income |
0.90 | 0.57 | 0.56 | 0.55 | |
Depreciation/Fixed assets |
0.12 | 0.26 | 0.18 | 0.15 | |
Capex/Depreciation |
(0.19) | (0.05) | 0.00 | 0.00 | |
Revenue per Share |
0.00 | 0.25 | 0.25 | 0.23 | |
Operating CF per Share |
(1.32) | (0.73) | (0.53) | (0.34) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 |
Columns are period end dates